FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2750588568> ?p ?o ?g. }

• W2750588568 endingPage "105" @default.
• W2750588568 startingPage "99" @default.
• W2750588568 abstract "Background & AimsIn women with inflammatory bowel diseases (IBDs), exposure to immunomodulator or biologic therapy has not been associated with adverse events during pregnancy or outcomes of newborns. We investigated whether exposure of patients to these agents during pregnancy affects serologic responses to vaccines in newborns.MethodsWe collected data from the Pregnancy in IBD and Neonatal Outcomes registry, which records outcomes of pregnant women with diagnosis of IBD receiving care at multiple centers in the United States, from 2007 through 2016. Serum samples collected from infants at least 7 months old were analyzed for titers of antibodies to Haemophilus influenzae B (HiB) or tetanus toxin; mothers completed a survey of vaccine practices and outcomes from July 2013 through October 2016. Umbilical cord blood samples from 33 infants were assayed for concentration of biologic agents. Vaccination response was compared between infants born to mothers exposed to biologic therapy (infliximab, adalimumab, certolizumab pegol, golimumab, natalizumab, vedolizumab, or ustekinumab—either as a single agent or in combination with an immunomodulator, at any time between conception and delivery) and infants born to unexposed mothers.ResultsA total of 179 women completed the vaccine survey (26 biologic unexposed, 153 exposed to a biologic agent). We found no significant difference in proportions of infants with protective antibody titers against HiB born to exposed mothers (n = 42, 71%) vs unexposed mothers (n = 8, 50%) (P = .41). We also found no difference in the proportion of infants with protective antibody titers to tetanus toxoid born to exposed mothers (80%) vs unexposed mothers (75%) (P = .66). The median concentration of infliximab in cord blood did not differ significantly between infants with vs without protective antibody titers to HiB (P = .30) or tetanus toxoid (P = .93). Mild reactions were observed in 7/40 infants who received rotavirus vaccine and whose mothers had been exposed to biologic therapies.ConclusionsVaccination of infants against HiB and tetanus toxin, based on antibody titers measured when infants were at least 7 months old, does not appear to be affected by in utero exposure to biologic therapy. In women with inflammatory bowel diseases (IBDs), exposure to immunomodulator or biologic therapy has not been associated with adverse events during pregnancy or outcomes of newborns. We investigated whether exposure of patients to these agents during pregnancy affects serologic responses to vaccines in newborns. We collected data from the Pregnancy in IBD and Neonatal Outcomes registry, which records outcomes of pregnant women with diagnosis of IBD receiving care at multiple centers in the United States, from 2007 through 2016. Serum samples collected from infants at least 7 months old were analyzed for titers of antibodies to Haemophilus influenzae B (HiB) or tetanus toxin; mothers completed a survey of vaccine practices and outcomes from July 2013 through October 2016. Umbilical cord blood samples from 33 infants were assayed for concentration of biologic agents. Vaccination response was compared between infants born to mothers exposed to biologic therapy (infliximab, adalimumab, certolizumab pegol, golimumab, natalizumab, vedolizumab, or ustekinumab—either as a single agent or in combination with an immunomodulator, at any time between conception and delivery) and infants born to unexposed mothers. A total of 179 women completed the vaccine survey (26 biologic unexposed, 153 exposed to a biologic agent). We found no significant difference in proportions of infants with protective antibody titers against HiB born to exposed mothers (n = 42, 71%) vs unexposed mothers (n = 8, 50%) (P = .41). We also found no difference in the proportion of infants with protective antibody titers to tetanus toxoid born to exposed mothers (80%) vs unexposed mothers (75%) (P = .66). The median concentration of infliximab in cord blood did not differ significantly between infants with vs without protective antibody titers to HiB (P = .30) or tetanus toxoid (P = .93). Mild reactions were observed in 7/40 infants who received rotavirus vaccine and whose mothers had been exposed to biologic therapies. Vaccination of infants against HiB and tetanus toxin, based on antibody titers measured when infants were at least 7 months old, does not appear to be affected by in utero exposure to biologic therapy." @default.
• W2750588568 created "2017-09-15" @default.
• W2750588568 creator A5019008409 @default.
• W2750588568 creator A5023182644 @default.
• W2750588568 creator A5026145145 @default.
• W2750588568 creator A5042813574 @default.
• W2750588568 creator A5062040636 @default.
• W2750588568 creator A5073977144 @default.
• W2750588568 date "2018-01-01" @default.
• W2750588568 modified "2023-10-12" @default.
• W2750588568 title "Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines" @default.
• W2750588568 cites W1964364579 @default.
• W2750588568 cites W1980639584 @default.
• W2750588568 cites W1984455842 @default.
• W2750588568 cites W2007749034 @default.
• W2750588568 cites W2030045078 @default.
• W2750588568 cites W2052160307 @default.
• W2750588568 cites W2059843231 @default.
• W2750588568 cites W2063459020 @default.
• W2750588568 cites W2085259429 @default.
• W2750588568 cites W2126148932 @default.
• W2750588568 cites W2129469955 @default.
• W2750588568 cites W2131198668 @default.
• W2750588568 cites W2142543286 @default.
• W2750588568 cites W2143233237 @default.
• W2750588568 cites W2149875127 @default.
• W2750588568 cites W2204471246 @default.
• W2750588568 cites W2316715874 @default.
• W2750588568 cites W2333584948 @default.
• W2750588568 cites W2333762130 @default.
• W2750588568 cites W2586027079 @default.
• W2750588568 cites W2597714858 @default.
• W2750588568 cites W315314819 @default.
• W2750588568 cites W4237793533 @default.
• W2750588568 doi "https://doi.org/10.1016/j.cgh.2017.08.041" @default.
• W2750588568 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5735029" @default.
• W2750588568 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28870657" @default.
• W2750588568 hasPublicationYear "2018" @default.
• W2750588568 type Work @default.
• W2750588568 sameAs 2750588568 @default.
• W2750588568 citedByCount "93" @default.
• W2750588568 countsByYear W27505885682018 @default.
• W2750588568 countsByYear W27505885682019 @default.
• W2750588568 countsByYear W27505885682020 @default.
• W2750588568 countsByYear W27505885682021 @default.
• W2750588568 countsByYear W27505885682022 @default.
• W2750588568 countsByYear W27505885682023 @default.
• W2750588568 crossrefType "journal-article" @default.
• W2750588568 hasAuthorship W2750588568A5019008409 @default.
• W2750588568 hasAuthorship W2750588568A5023182644 @default.
• W2750588568 hasAuthorship W2750588568A5026145145 @default.
• W2750588568 hasAuthorship W2750588568A5042813574 @default.
• W2750588568 hasAuthorship W2750588568A5062040636 @default.
• W2750588568 hasAuthorship W2750588568A5073977144 @default.
• W2750588568 hasBestOaLocation W27505885681 @default.
• W2750588568 hasConcept C126322002 @default.
• W2750588568 hasConcept C131872663 @default.
• W2750588568 hasConcept C187212893 @default.
• W2750588568 hasConcept C197934379 @default.
• W2750588568 hasConcept C203014093 @default.
• W2750588568 hasConcept C22070199 @default.
• W2750588568 hasConcept C2776215756 @default.
• W2750588568 hasConcept C2776283161 @default.
• W2750588568 hasConcept C2777138892 @default.
• W2750588568 hasConcept C2777351567 @default.
• W2750588568 hasConcept C2779134260 @default.
• W2750588568 hasConcept C2779234561 @default.
• W2750588568 hasConcept C2779841045 @default.
• W2750588568 hasConcept C2780132546 @default.
• W2750588568 hasConcept C54355233 @default.
• W2750588568 hasConcept C71924100 @default.
• W2750588568 hasConcept C86803240 @default.
• W2750588568 hasConceptScore W2750588568C126322002 @default.
• W2750588568 hasConceptScore W2750588568C131872663 @default.
• W2750588568 hasConceptScore W2750588568C187212893 @default.
• W2750588568 hasConceptScore W2750588568C197934379 @default.
• W2750588568 hasConceptScore W2750588568C203014093 @default.
• W2750588568 hasConceptScore W2750588568C22070199 @default.
• W2750588568 hasConceptScore W2750588568C2776215756 @default.
• W2750588568 hasConceptScore W2750588568C2776283161 @default.
• W2750588568 hasConceptScore W2750588568C2777138892 @default.
• W2750588568 hasConceptScore W2750588568C2777351567 @default.
• W2750588568 hasConceptScore W2750588568C2779134260 @default.
• W2750588568 hasConceptScore W2750588568C2779234561 @default.
• W2750588568 hasConceptScore W2750588568C2779841045 @default.
• W2750588568 hasConceptScore W2750588568C2780132546 @default.
• W2750588568 hasConceptScore W2750588568C54355233 @default.
• W2750588568 hasConceptScore W2750588568C71924100 @default.
• W2750588568 hasConceptScore W2750588568C86803240 @default.
• W2750588568 hasIssue "1" @default.
• W2750588568 hasLocation W27505885681 @default.
• W2750588568 hasLocation W27505885682 @default.
• W2750588568 hasLocation W27505885683 @default.
• W2750588568 hasLocation W27505885684 @default.
• W2750588568 hasLocation W27505885685 @default.
• W2750588568 hasOpenAccess W2750588568 @default.
• W2750588568 hasPrimaryLocation W27505885681 @default.
• W2750588568 hasRelatedWork W1569284502 @default.

• next